Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer Clinical Trial

Official title:

The LIMIT KRAS Mutant NSCLC Trial: Lysosome Inhibition to Enhance MAPK Inhibition Targeting KRAS Mutant NSCLC: A Phase 2 Open Label Trial of Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04735068
• Other study ID #: UPCC 21520
• Secondary ID: 844511
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: April 9, 2021
• Est. completion date: December 2023

Study information

• Verified date: June 2023
• Source: Abramson Cancer Center at Penn Medicine
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will evaluate using hydroxychloroquine (HCQ) along with binimetinib as an effective method for treating cancer. All patients will receive binimetinib at a standard dose approved for other cancers. The dose of HCQ will also be fixed based on ongoing phase I studies. Eligible subjects will have lung cancer that has a mutation in a key cancer gene called KRAS, and the cancer has spread to other parts of their body.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 11
• Est. completion date: December 2023
• Est. primary completion date: August 21, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Metastatic or incurable NSCLC

2. Presence of a non-synonymous mutation in KRAS

3. Patient must have received at least one prior systemic therapy for metastatic NSCLC or be intolerant/ineligible/refuse available therapies with known benefit

4. Ability and willingness to sign a written informed consent document

5. Age =18 years old

6. At least one measureable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1

7. ECOG performance status 0-1

8. Adequate organ function

9. Women of childbearing potential must have a negative serum pregnancy test performed within 72hours of the first dose of study therapy. Subjects of reproductive potential must agree to use acceptable birth control methods (see Appendix B for childbearing potential).

10. Qtc < 500 mSec on EKG

11. Must be able to swallow tablets

12. Must be willing to comply with protocol procedures (including completion of diaries and outcome measures

Exclusion Criteria:

1. Currently participating in or has participated in a study of an investigational agent or anticipated use of an investigational device within 4 weeks of the first dose of study treatment.

2. Untreated symptomatic central nervous system (CNS) metastases and/or carcinomatous meningitis.

3. Prior monoclonal antibody within 4 weeks prior to enrollment, or individuals who have not recovered (i.e., = Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier.

4. Known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, non-invasive bladder tumors, or in situ cervical cancer

5. Active infection requiring systemic therapy with IV antibiotics

6. History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.

7. Known psychiatric or substance abuse disorders as documented in the chart that, in the opinion of the investigator, would interfere with cooperation with the requirements of the trial.

8. Pregnant or breastfeeding women

9. Anticipated receipt of any live vaccine within 30 days prior to the first dose of trial treatment.

10. Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to study drug, or excipients or to dimethyl sulfoxide (DMSO).

11. Patients receiving cytochrome P450 enzyme-inducing anticonvulsant drugs (EIADs) (i.e. phenytoin, carbamazepine, Phenobarbital, primidone or oxcarbazepine) within 4 weeks of the start of the study treatment

12. Known Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) infection (subjects with laboratory evidence of cleared HBV and/or HCV will be permitted)

13. Patients with a previously documented retinal vein occlusion.

14. History or evidence of increased cardiovascular risk including any of the following:

• Current clinically significant uncontrolled arrhythmias. Exception: Subjects with controlled atrial fibrillation for > 30 days prior to randomization are eligible.
• History of acute coronary syndromes (including myocardial infarction and unstable angina), coronary angioplasty, or stenting within 6 months prior to randomization.
• Ejection fraction of =50% as measured by echocardiography or MUGA

15. Any other conditions judged by the investigator that would limit the evaluation of the subject

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• KRAS Mutation-Related Tumors
• Lung Neoplasms
• Non-Small Cell Lung Cancer

Intervention

Drug:
• Binimetinib Pill
Patients will be treated with B 45 mg two times daily and HCQ 400 mg twice daily beginning on day 1. The dose of HCQ is based on an ongoing Phase 1 trial, and may be modified in a future amendment prior to the first patient enrolled. Efforts will be made to ensure dose homogeneity throughout the trial. Treatment will be administered on an outpatient basis on a 28 day cycle
• Hydroxychloroquine Pill
Patients will be treated with B 45 mg two times daily and HCQ 400 mg twice daily beginning on day 1. The dose of HCQ is based on an ongoing Phase 1 trial, and may be modified in a future amendment prior to the first patient enrolled. Efforts will be made to ensure dose homogeneity throughout the trial. Treatment will be administered on an outpatient basis on a 28 day cycle

Locations

Country	Name	City	State
United States	Abramson Cancer Center of the University of Pennsylvania	Philadelphia	Pennsylvania

Sponsors (2)

Lead Sponsor	Collaborator
Abramson Cancer Center at Penn Medicine	Pfizer

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Objective Response Rate		2 years
Primary	Number of Patients with Adverse Events as assessed by CTCAE v5.0		2 years
Secondary	progression-free survival (PFS)		2 years
Secondary	Number of changes in ctDNA KRAS allelic frequency (blood)		2 years
Secondary	Overall survival (OS)		2 years